Latest Product Pipeline News

Evolution Mining (ASX: EVN) is set to acquire Carnaby Resources (ASX: CNB) in a $213 million deal that expands its copper production pipeline near Ernest Henry, leveraging existing infrastructure and latent mill capacity.

Resonance Health (ASX:RHT) closed FY26 with a net operating cash inflow of $2.9 million and completed recruitment for a $13.8 million clinical trial, underpinning a robust contract pipeline and growing net cash position.

PolyNovo has delivered solid FY26 revenue growth of 16.1%, driven by commercial sales expansion and improved manufacturing output, while progressing insurance recovery from its R&D centre fire.

Aeris Resources has secured the critical mining lease for its Constellation Project at Tritton Copper Operations, unlocking the path to production with early construction already underway and waste stripping set for early next year.

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

Immuron Limited reported a 6% increase in FY26 sales to AUD 7.7 million, driven by strong gains in Canada and the US despite mixed Australian performance. Marketing initiatives and retail expansion underpin growth.

Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.

Aquirian Limited reported a near tripling of EBITDA to $4.6 million in FY26, driven by a $48 million contract win for its Drillforce subsidiary and expanded production capacity at its Wubin facility.

ReNerve Limited has secured regulatory approval to market its flagship NervAlign Nerve Cuff in Indonesia, marking a major step in its Asia-Pacific expansion and unlocking access to one of the region’s largest nerve repair markets.

BCAL Diagnostics has acquired a 10.2% stake in Genetic Signatures for $1.39 million, aiming to merge early cancer detection with infectious disease diagnostics and expand its international footprint.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.